Abstract: An array substrate, a display panel, and a display device are provided. The array substrate comprises a plurality of pixel regions in an array along intersected first and second directions. The pixel region includes at least three subpixel regions. At least one subpixel region serves as an adjustment-subpixel region. The subpixel region has a first electrode including at least two parallel first straight portions. Second straight portions and first connecting portions are connected to first and second ends of the first straight portions, respectively. The first electrode corresponding to the adjustment-subpixel region serves as an adjustment electrode. An opening is configured at an end between the at least two adjacent second straight portions corresponding to the adjustment electrode. An angle between extending direction of the first straight portion and the second direction is less than an angle between extending direction of the second straight portion and the second direction.

Abstract: The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.

Abstract: The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.

Abstract: The invention discloses a method for preparing a hollow textile with a core-spun yarn of short-staple wrapped microporous alkali-soluble polyester filament, which includes a foaming microcapsule preparation step, a preparation step of alkali-soluble chips containing foaming microcapsules, a melt foaming and spinning step, and a hollow textile preparation step. In the method for preparing the hollow textile with the core-spun yarn of short-staple wrapped microporous alkali-soluble polyester filament, a hollow yarn or a hollow fabric is made from a polyester filament having a microporous structure through alkali dissolution. The polyester filament having a microporous structure can effectively increase the contact area of the alkali dissolution and has the advantages of high dissolution rate, short dissolution time and complete dissolution.

Abstract: The present disclosure relates to a liquid crystal display panel and a display device. The liquid crystal display panel includes a display area; and a non-display area surrounding the display area, wherein the display area includes a plurality of sub-areas, each of the plurality of sub-areas is provided with a plurality of pixel electrodes, all of the pixel electrodes in a sub-area have an identical brightness control parameter; and the brightness control parameter of the pixel electrodes in at least one sub-area is different from the brightness control parameter of the pixel electrodes in another sub-area. By setting different brightness control parameters based on different temperature rise in the sub-areas, the problem of poor Gamma uniformity of the display panel can be solved, and the possibility of occurrence of ghost can be reduced, thereby increasing display quality of the liquid crystal display panel.

Abstract: The present invention relates to methods for determining whether a subject having prostate cancer is at an increased risk for relapse or rapid relapse. It is based, at least in part, on the results of a comprehensive genome analysis of 273 prostate cancer samples, which indicate that the percentage of large size CNVs predicts prostate cancer relapse. In certain embodiments, a method for determining whether a prostate cancer patient has an increased risk of suffering a relapse or a rapid relapse comprises determining the number and size of CNVs in a sample and determining a large size ratio, where if the large size ratio exceeds a particular threshold, the patient is deemed to be at an increased risk for relapse or rapid relapse.

Abstract: The present application discloses a novel light flame-retardant heat-insulated warm-retention protective fabric and a preparation method thereof. The preparation method comprises the steps of making soluble fibers and wrapping fibers into core spun yarns by ring spun core-spun spinning method, and weaving the made core spun yarns into a grey fabric by a loom; and then dissolving the soluble fibers in the grey fabric, and finally making the grey fabric into the novel light flame-retardant heat-insulated warm-retention protective fabric upon dyeing and finishing procedures. The protective fabric is a hollow yarn fabric and includes conventional woven goods and knit goods, still air will be generated among the yarns. With respect to the protective fabric with flowing air in the prior art, the protective fabric of the present invention has the advantages of better heat insulation and warm retention, lighter weight and stronger comfort.

Abstract: The present invention discloses a warp-knitted fabric of filament and short staple composite yarn and a preparation method thereof. The warp-knitted fabric of filament and short staple composite yarn is prepared by the corresponding preparation method for the warp-knitted fabric of filament and short staple composite yarn. The preparation method for the warp-knitted fabric of filament and short staple composite yarn has excellent weavability, and can effectively prepare the warp-knitted fabric which is high in size stability, is soft, has high elasticity, is wrinkle-resistant and has an excellent hand feeling and comfort. Moreover, in the preparation method, soluble fiber filaments can be added to prepare a warp-knitted fabric or a 3D interval warp-knitted fabric which is partially or entirely formed by 100% short staple yarns; and low-melting-point filaments can also be added to prepare a warp-knitted fabric which can be randomly cut and has no edge curling variation.

Abstract: The invention discloses a technology for recovery, regeneration and reuse of soluble textiles. The technology comprises the steps of: the dissolution-controlled soluble polyester fibres are processed into soluble apparel accessories through conventional weaving, dyeing, finishing and tailoring or injection molding; the apparels or the soluble apparel accessories are dissolved under a certain condition, on one hand, the dissolving solution is filtered and solutes are recovered to obtain a high purity of terephthalic acid and ethylene glycol, which are reused to the polymerization of the soluble polyester, and the slices of the soluble polyester are obtained to be re-spun into the soluble fibres for reuse; on the other hand, the incompact and undissolved textiles are treated into an incompact fibre aggregation with good qualities by processes including disinfection, decolourization or redyeing, which are processed into high-quality textile fibres for reuse after drying or softly carding.

Abstract: Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

Abstract: The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.

Abstract: A capsule containing total flavonoids of Desmodium styracifolium, a method for preparing the same and a use of the capsule containing total flavonoids of Desmodium styracifolium are provided. Specifically, the capsule includes total flavonoids of Desmodium Styracifolium provided in a form of alcohol extract of Desmodium Styracifolium and a pharmaceutically acceptable excipient.

Abstract: The present invention discloses a method for preparing untwisted, hollow, high-count textiles comprising the following steps: a. preparing an alkaline degradable slice; b. preparing a blended spun melt; c. preparing an easily alkaline soluble and degradable fiber by spinning; d. preparing the textiles or an embroidered article. A method for recovering the solute in an alkaline lysis solution comprises an alkaline lysis solution obtained after the degradation of the easily alkaline soluble and degradable fiber is subjected to an acid precipitation, so as to produce terephthalic acid, wherein the waste water obtained by filtering meets the emission standard and is introduced to a biochemistry processing system.

Abstract: A solid dispersion containing Desmodium Styracifolium (Osb.) Merr. flavonoids, method of preparing same and use thereof. The Desmodium Styracifolium (Osb.) Merr. flavonoids are alcohol extract of Desmodium Styracifolium (Osb.) Merr., and the solid dispersion is used for preparing a drug for treating urinary tract calculi.

Abstract: Disclosed are a pharmaceutical composition, a method for preparing the same and use thereof. The pharmaceutical composition consists of total flavonoids of Desmodium Styracifolium as an active ingredient and a pharmaceutically acceptable excipient. The pharmaceutical composition can be formulated in a form of a medicament formulation suitable to administration in clinic, and can be used in preparation of clinic treatment medicaments for treating dampness-heat and urinary stone (stagnation of dampness-heat).

Abstract: A capsule containing total flavonoids of Desmodium styracifolium, a method for preparing the same and a use of the capsule containing total flavonoids of Desmodium styracifolium are provided. Specifically, the capsule includes total flavonoids of Desmodium Styracifolium provided in a form of alcohol extract of Desmodium Styracifolium and a pharmaceutically acceptable excipient.

Abstract: The invention discloses the processing method of a non-PVA fiber hollow yarn and the tubular fabric. The fiber shall include filament yarn, staple yarn and ribbon. The processing method applies degradable fiber which is controllable in degradation conditions and has none formaldehyde residue to produce hollow yarn, in contrast with conventional soluble Vinylon hollow yarn, which is environmentally friendly and cheap while has low shrinkage and distinct hollow effect as can be made into high density textile and single yarn textile through sizing process. Furthermore, the tubular fabric as described in this invention spinned with the non-PVA fiber hollow yarn is feature with lightness, fluffy sense, warmth, moisture absorption and softness.

Abstract: The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.

Abstract: The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.